panbronchiolitis%20-%20diffuse
PANBRONCHIOLITIS - DIFFUSE
Diffuse panbronchiolitis is an inflammatory disease affecting the respiratory bronchioles.
It causes progressive suppurative and obstructive respiratory disease.
This is an idiopathic disease which is primarily found in Japan, Korea and China.
Predisposition to the disease may be genetically-related but environmental factors should also be considered.
Failure to treat diffuse panbronchiolitis can lead to development of bronchiectasis, progressive failure and death.

Panbronchiolitis%20-%20diffuse Treatment

Pharmacotherapy

  • Macrolides should be started as soon as diagnosis is established

Macrolides

  • Eg Erythromycin,14 member-ringed macrolides (eg Clarithromycin, Roxithromycin), & the 15 member-ringed macrolide Azithromycin
  • Erythromycin is the 1st choice in treatment of diffuse panbronchiolitis (DPB)
    • Treatment duration is for at least 6 months
  • Other macrolides (Clarithromycin, Roxithromycin, Azithromycin) are used when Erythromycin is ineffective or not tolerated
  • Studies show better lung function (decreased dyspnea, opacities in HRCT) w/ Azithromycin use in patients w/ DPB

Actions:

  • Inhibit production of pro-inflammatory cytokines & formation of leukotriene B4
  • Block the formation of adhesion molecules required for migration of neutrophils

Effects:

  • Decreased inflammation of the airways, leading to improved pulmonary function & decreased infection
  • Erythromycin helps improve host defense & regulate bacterial activities
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Feb 2021
Invasive ventilation using a lower positive end-expiratory pressure (PEEP) strategy was noninferior to higher PEEP in ICU* patients without acute respiratory distress syndrome (ARDS), according to the RELAx** study presented at eCCR 2021.
Audrey Abella, 29 Mar 2018
Food continues to be the most common trigger for anaphylaxis, a rapid-onset and potentially fatal hypersensitivity reaction, according to evidence presented at the AAAAI/WAO* Joint Congress 2018 held in Orlando, Florida, US.

Jairia Dela Cruz, 19 Feb 2021
Among critically ill adults receiving mechanical ventilation in the intensive care unit (ICU), a protocol of no sedation is comparable to light sedation with daily interruption in terms of mortality, as shown in the NONSEDA trial.